Plant Name: Lonicera hypoglauca
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NPSR1; CXCR1; NMUR2; | |
| ADRA2C; ADRA2A; GPBAR1; DRD4; | |
| ALPI; PLA2G1B; TDP1; RECQL; PIK3R1; GLO1; MPO; AKR1B1; HSD17B10; ALOX15; HSD11B1; HSD17B2; ALOX12; AKR1B10; NOX4; TNKS; PARP1; TNKS2; PYGL; POLB; CD38; | |
| PTPRF; PTPN1; CDC25B; PTPN2; ACP1; | |
| ACHE; GAA; | |
| AKT1; MET; CSNK2A1; DAPK1; AXL; NEK2; FLT3; NEK6; PKN1; CAMK2B; SRC; IGF1R; PTK2; AURKB; GSK3B; CDK1; MAPK1; PIM1; NUAK1; ALK; KDR; | |
| CA9; CA5B; CA5A; CA3; CA14; CA7; CA4; CA6; CA2; CA12; CA1; | |
| PPARA; PPARD; | |
| RORC; | |
| NR1H4; | |
| KDM4E; | |
| MAOA; ALOX5; XDH; | |
| MMP13; MMP12; MMP3; MMP2; MMP9; MMP1; | |
| BACE1; | |
| TLR2; | |
| STAT6; HIF1A; NFKB1; TP53; | |
| ABCC1; ABCG2; | |
| SLCO1B3; SLCO1B1; | |
| LMNA; FABP5; FABP2; FABP4; FABP3; APP; TTR; | |
| L3MBTL1; SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
| Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
| Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
| Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.481E-09 | 5.936E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.346E-09 | 1.109E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, NOX4 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 8.871E-09 | 1.740E-06 | ADRA2A, AURKB, CA2, CA7, CD38, HIF1A, KDR, MAPK1, NEK2, NPSR1, NR1H4, PARP1, PLA2G1B, SRC, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 1.245E-08 | 2.279E-06 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, MAPK1, PKN1, TNKS |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 1.745E-08 | 2.952E-06 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B, TLR2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.213E-08 | 3.569E-06 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, XDH |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 2.920E-08 | 4.354E-06 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 2.967E-08 | 4.395E-06 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, MAPK1, NEK6, PKN1, SRC, TNKS |
| MF | GO:0005488; binding | GO:0020037; heme binding | 4.176E-08 | 5.830E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, MPO, NOX4, SRC |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 5.375E-08 | 7.050E-06 | ABCG2, ACHE, ADRA2A, ADRA2C, AKT1, ALK, APP, CAMK2B, CD38, CSNK2A1, DAPK1, DRD4, FLT3, IGF1R, KDR, L3MBTL1, MAPK1, MET, MMP9, NFKB1, PARP1, PYGL, SMN1, SMN2, STAT6, TP53, TTR, XDH |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 5.624E-08 | 7.174E-06 | AURKB, CA2, CA7, HIF1A, MAPK1, NEK2, NPSR1, NR1H4, PLA2G1B, TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 1.126E-07 | 1.332E-05 | ABCC1, ABCG2, AKT1, ALK, AURKB, AXL, CAMK2B, CDK1, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MAPK1, MET, NEK2, NEK6, NUAK1, PIM1, PKN1, PTK2, PYGL, RECQL, SRC, TP53 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.408E-07 | 1.622E-05 | HIF1A, MMP1, MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 1.688E-07 | 1.935E-05 | MMP1, MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.891E-07 | 2.123E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C8 |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 2.334E-07 | 2.542E-05 | AKT1, ALK, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, GSK3B, MAPK1, NEK2, NEK6, NUAK1, PIM1, PKN1 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 5.246E-07 | 5.010E-05 | HIF1A, MMP1, MMP12, MMP13, MMP2, MMP3, MMP9 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.772E-07 | 6.290E-05 | CYP1A2, CYP2C8, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 1.217E-06 | 1.077E-04 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 1.678E-06 | 1.440E-04 | MMP1, MMP12, MMP13, MMP2, MMP3, MMP9 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.686E-06 | 1.440E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 2.784E-06 | 2.254E-04 | ADRA2A, ADRA2C, AKT1, AXL, MAPK1, PIK3R1, SRC |
| BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 3.098E-06 | 2.426E-04 | ADRA2A, AKT1, HIF1A, NOX4, NR1H4, PIK3R1, PTPN2, PYGL |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 3.358E-06 | 2.600E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.140E-06 | 3.781E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C8 |
| BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 5.301E-06 | 3.874E-04 | MMP1, MMP12, MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0050896; response to stimulus | GO:0046626; regulation of insulin receptor signaling pathway | 7.804E-06 | 5.500E-04 | NR1H4, PIK3R1, PTPN1, PTPN2, SRC |
| MF | Unclassified; | GO:0032403; protein complex binding | 8.609E-06 | 5.960E-04 | ACHE, ADRA2A, FLT3, IGF1R, KDR, MMP12, MMP13, MMP9, PIK3R1, PPARA, PTPN1, PTPN2, PTPRF, SRC, TLR2, TSHR |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 9.327E-06 | 6.387E-04 | ADRA2A, ADRA2C, DRD4 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 9.850E-06 | 6.640E-04 | ABCC1, ADRA2A, CA2, CA4, CA9, SLCO1B1, SLCO1B3, TSHR |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.068E-05 | 7.177E-04 | FABP2, FABP3, FABP4, FABP5 |
| MF | GO:0005488; binding | GO:0032052; bile acid binding | 1.393E-05 | 9.111E-04 | NR1H4, PLA2G1B, PYGL |
| BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 1.469E-05 | 9.491E-04 | PARP1, SRC, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 1.469E-05 | 9.491E-04 | APP, GSK3B, IGF1R, PARP1 |
| BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 1.572E-05 | 1.007E-03 | ALK, CDK1, DRD4, MAPK1, PKN1, PLA2G1B, PTPN1 |
| BP | GO:0032502; developmental process | GO:0051094; positive regulation of developmental process | 2.114E-05 | 1.289E-03 | ADRA2C, AKT1, ALOX12, APP, AXL, CA2, CAMK2B, CDK1, CYP1B1, HIF1A, KDR, LMNA, NFKB1, NR1H4, PARP1, PIM1, PPARD, SRC, STAT6, TLR2 |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 2.309E-05 | 1.389E-03 | AKR1B1, AXL, CDK1, CYP1B1, STAT6 |
| BP | GO:0008152; metabolic process | GO:0042446; hormone biosynthetic process | 2.309E-05 | 1.389E-03 | AKR1B1, CYP19A1, CYP3A4, HSD11B1, HSD17B2 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 2.585E-05 | 1.519E-03 | AKT1, HIF1A, LMNA, PPARD, SRC, TP53 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 2.589E-05 | 1.519E-03 | AKT1, CYP1A2, MAPK1, MMP9 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 2.761E-05 | 1.603E-03 | AKT1, APP, CYP1A1, CYP1B1, FLT3, MAPK1, NFKB1, NOX4, RORC, SRC |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 3.097E-05 | 1.770E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 3.097E-05 | 1.770E-03 | ALOX12, ALOX15 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.605E-05 | 2.008E-03 | CYP1A2, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 3.605E-05 | 2.008E-03 | CYP1A2, CYP2C8, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 3.766E-05 | 2.076E-03 | ADRA2A, ADRA2C, AKT1, SRC |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 4.373E-05 | 2.363E-03 | AKR1B1, AKT1, ALOX5, AURKB, CAMK2B, CDC25B, CDK1, CSNK2A1, FABP5, GSK3B, HIF1A, L3MBTL1, LMNA, MAPK1, NEK2, NEK6, NFKB1, NR1H4, NUAK1, PARP1, PIM1, PKN1, POLB, PPARA, PPARD, PTPN2, RECQL, RORC, SMN1, SMN2, SRC, STAT6, TNKS, TP53 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 4.561E-05 | 2.452E-03 | CYP19A1, NFKB1, NR1H4, PPARA, PPARD, PTPN2 |
| MF | GO:0003824; catalytic activity | GO:0004222; metalloendopeptidase activity | 4.561E-05 | 2.452E-03 | MMP1, MMP12, MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0009987; cellular process | GO:1900103; positive regulation of endoplasmic reticulum unfolded protein response | 4.667E-05 | 2.481E-03 | PIK3R1, PTPN1, PTPN2 |
| BP | GO:0032502; developmental process | GO:0007568; aging | 4.671E-05 | 2.481E-03 | AKT1, AURKB, CDK1, CYP1A1, MPO, NOX4, POLB, TP53 |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 5.171E-05 | 2.694E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
| BP | GO:0009987; cellular process | GO:0045595; regulation of cell differentiation | 5.680E-05 | 2.924E-03 | ADRA2C, AKT1, APP, AXL, CA2, CAMK2B, CDK1, GSK3B, HIF1A, KDR, L3MBTL1, MAPK1, NFKB1, PARP1, PIK3R1, PPARA, PPARD, PTK2, PTPN2, PTPRF, RORC, TLR2, XDH |
| BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 6.175E-05 | 3.142E-03 | ABCG2, APP, CA12, CA2, CA7, CD38, DRD4, HIF1A, MAPK1, NMUR2, NPSR1, PLA2G1B, TP53 |
| BP | GO:0065007; biological regulation | GO:0051090; regulation of DNA binding transcription factor activity | 6.418E-05 | 3.257E-03 | AKT1, ALK, APP, CYP1B1, MAPK1, NFKB1, NR1H4, PIM1, PLA2G1B, TLR2 |
| BP | GO:0008152; metabolic process | GO:0031331; positive regulation of cellular catabolic process | 7.445E-05 | 3.701E-03 | ADRA2A, AKT1, CDK1, DAPK1, GSK3B, HIF1A, KDR, PPARA, PTK2, PTPN1 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 7.587E-05 | 3.763E-03 | ACP1, AKR1B1, AKR1B10, AKT1, ALOX12, ALOX15, ALOX5, APP, AURKB, CA1, CA2, CA3, CA7, CAMK2B, CDC25B, CDK1, CSNK2A1, FABP2, FABP3, FABP4, FABP5, FLT3, GLO1, GSK3B, HIF1A, LMNA, MAPK1, NEK2, NEK6, NFKB1, PIK3R1, PIM1, PKN1, PLA2G1B, PTK2, PTPN1, PTPN2, PYGL, SMN1, SMN2, SRC, STAT6, TNKS, TNKS2, TP53, XDH |
| BP | GO:0065007; biological regulation | GO:0030003; cellular cation homeostasis | 7.831E-05 | 3.867E-03 | ABCG2, APP, CA2, CA7, CD38, DRD4, HIF1A, MAPK1, NMUR2, NPSR1, PLA2G1B, TP53 |
| BP | GO:0002376; immune system process | GO:0043312; neutrophil degranulation | 8.142E-05 | 4.002E-03 | ALOX5, CXCR1, FABP5, GAA, MAPK1, MMP9, MPO, NFKB1, PYGL, TLR2, TTR |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 8.576E-05 | 4.150E-03 | AKT1, FABP3, NR1H4, SRC, TLR2 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 9.028E-05 | 4.349E-03 | ALOX12, ALOX15, ALOX5 |
| BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 9.258E-05 | 4.364E-03 | APP, TLR2 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 9.258E-05 | 4.364E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 9.258E-05 | 4.364E-03 | GPBAR1, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 9.258E-05 | 4.364E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 9.258E-05 | 4.364E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 9.258E-05 | 4.364E-03 | ADRA2A, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 9.258E-05 | 4.364E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 9.258E-05 | 4.364E-03 | GPBAR1, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0046209; nitric oxide metabolic process | 1.092E-04 | 4.984E-03 | AKT1, CYP1B1, TLR2 |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 1.092E-04 | 4.984E-03 | AURKB, CDK1, PKN1 |
| BP | GO:0002376; immune system process | GO:0002521; leukocyte differentiation | 1.096E-04 | 4.994E-03 | AXL, FLT3, GLO1, MMP9, PARP1, PIK3R1, PTPN2, RORC |
| BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 1.154E-04 | 5.182E-03 | AKT1, LMNA, MMP9, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 1.245E-04 | 5.522E-03 | ADRA2C, AKT1, ALOX12, APP, AXL, CA2, CAMK2B, CDK1, CYP1B1, GSK3B, HIF1A, KDR, L3MBTL1, NR1H4, PIK3R1, PIM1, PPARD, PTK2, PTPN2, PTPRF, SRC, STAT6, TLR2, XDH |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.370E-04 | 5.990E-03 | IGF1R, KDR, PTK2, SRC |
| BP | Unclassified; | GO:1905953; negative regulation of lipid localization | 1.370E-04 | 5.990E-03 | AKT1, NFKB1, PPARA, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0001523; retinoid metabolic process | 1.500E-04 | 6.532E-03 | AKR1B10, CYP1A1, CYP1B1, PPARD, TTR |
| BP | Unclassified; | GO:0032845; negative regulation of homeostatic process | 1.585E-04 | 6.815E-03 | ADRA2A, CD38, PARP1, SRC, TNKS, TNKS2 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 1.613E-04 | 6.888E-03 | NR1H4, PPARA, PPARD, RORC |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.688E-04 | 7.179E-03 | CA2, CA7, KDR, NPSR1, PARP1, PLA2G1B, SRC |
| BP | GO:0065007; biological regulation | GO:0032431; activation of phospholipase A2 activity | 1.845E-04 | 7.623E-03 | NMUR2, PLA2G1B |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 1.845E-04 | 7.623E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 1.845E-04 | 7.623E-03 | ADRA2A, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 1.845E-04 | 7.623E-03 | TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 1.845E-04 | 7.623E-03 | PTPN1, PTPN2 |
| BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 1.845E-04 | 7.623E-03 | APP, TLR2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.845E-04 | 7.623E-03 | CYP1A1, CYP1A2 |
| BP | GO:0009987; cellular process | GO:0051983; regulation of chromosome segregation | 1.934E-04 | 7.947E-03 | AURKB, CSNK2A1, NEK2, NEK6, TNKS |
| BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 1.934E-04 | 7.947E-03 | AKT1, HIF1A, MMP9, PTPN1, SRC |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 1.956E-04 | 7.991E-03 | AXL, CSNK2A1, DRD4, GSK3B, PPARA, RORC, SRC, TP53 |
| BP | GO:0008152; metabolic process | GO:0016311; dephosphorylation | 1.956E-04 | 7.991E-03 | ACP1, ALPI, CA3, CDC25B, POLB, PTPN1, PTPN2, PTPRF |
| BP | GO:0009987; cellular process | GO:0032872; regulation of stress-activated MAPK cascade | 2.068E-04 | 8.371E-03 | AKT1, APP, IGF1R, MAPK1, PKN1, PTPN1, XDH |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 2.101E-04 | 8.472E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.127E-04 | 8.536E-03 | AXL, MET, NOX4, PIK3R1, PTK2, SRC |
| BP | GO:0008152; metabolic process | GO:0035335; peptidyl-tyrosine dephosphorylation | 2.346E-04 | 9.309E-03 | ACP1, CDC25B, PTPN1, PTPN2, PTPRF |
| BP | GO:0008152; metabolic process | GO:0005977; glycogen metabolic process | 2.357E-04 | 9.309E-03 | AKT1, GAA, GSK3B, PYGL |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 2.357E-04 | 9.309E-03 | NOX4, PARP1, POLB, TP53 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.325E-22 | 2.885E-18 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.512E-16 | 1.013E-12 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.390E-15 | 5.975E-12 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.829E-14 | 3.625E-11 | ALPI, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, GLO1, L3MBTL1, MMP1, MMP12, MMP13, MMP2, MMP3, MMP9, NR1H4, PARP1, PPARA, PPARD, PTPN1, RORC, TNKS, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 8.124E-22 | 1.544E-19 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 4.750E-12 | 4.512E-10 | CAMK2B; SRC; MMP2; PIK3R1; HIF1A; MMP9; PTK2; IGF1R; KDR; AKT1; MAPK1; TP53; MET; TLR2 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 4.147E-10 | 2.626E-08 | GSK3B; FLT3; MMP1; DAPK1; MMP2; PIK3R1; HIF1A; MMP9; NFKB1; PTK2; IGF1R; AKT1; MAPK1; MET; TP53; PPARD |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.126E-09 | 1.010E-07 | MMP1; DAPK1; SRC; MMP2; MAPK1; MMP9; TP53 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 6.236E-09 | 2.370E-07 | PTPN1; CSNK2A1; SRC; MAPK1; ACP1; MET; PTPRF; IGF1R |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 2.329E-08 | 7.157E-07 | FLT3; PIM1; AKT1; MAPK1; PIK3R1; NFKB1; PPARD |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 9.728E-08 | 1.848E-06 | SRC; AKT1; MAPK1; STAT6; PIK3R1; TP53; MMP9; NFKB1; TLR2 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 7.329E-08 | 1.741E-06 | FLT3; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.637E-08 | 7.157E-07 | HSD11B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 3.205E-07 | 4.684E-06 | GSK3B; KDR; AKT1; MAPK1; PIK3R1; PKN1; TP53; MET; PTK2; NFKB1; TLR2; IGF1R |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.345E-07 | 2.324E-06 | PTPN1; GSK3B; AKT1; PIK3R1; PYGL; PPARA; NFKB1; PTPRF |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 9.012E-08 | 1.848E-06 | FABP2; FABP3; FABP4; FABP5; MMP1; PPARA; PPARD |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.824E-07 | 4.471E-06 | ALOX5; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 5.268E-07 | 6.256E-06 | GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 4.507E-07 | 5.709E-06 | CAMK2B; GSK3B; SRC; AKT1; MAPK1; PIK3R1; PTK2 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 5.772E-07 | 6.451E-06 | FLT3; MMP3; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.375E-06 | 1.353E-05 | CAMK2B; AKT1; MAPK1; PIK3R1; TP53; IGF1R |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 1.511E-06 | 1.367E-05 | GSK3B; SRC; KDR; AKT1; MAPK1; PIK3R1; MET; PTK2; IGF1R |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 9.403E-07 | 9.926E-06 | SRC; KDR; AKT1; MAPK1; PIK3R1; PTK2 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.424E-06 | 1.353E-05 | CAMK2B; AKT1; MAPK1; PIK3R1; HIF1A; NFKB1; IGF1R |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 2.322E-06 | 1.917E-05 | AKT1; MAPK1; PIK3R1; TP53; MET; IGF1R |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.502E-06 | 1.917E-05 | APP; CYP2C8; MAOA; ALOX5; ALOX15; MAPK1; ALOX12 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 2.522E-06 | 1.917E-05 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 3.546E-06 | 2.592E-05 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; TP53; HIF1A |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 3.966E-06 | 2.791E-05 | CAMK2B; GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 9.331E-06 | 5.372E-05 | PLA2G1B; MAOA; GAA; ALOX15; AKR1B1; ALOX12; PYGL; CYP3A4; CYP19A1; HSD17B10; HSD11B1; CYP2C8; AKR1B10; ALOX5; HSD17B2; CYP1A2; CYP1A1; CD38; ALPI; XDH |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 7.976E-06 | 5.051E-05 | GSK3B; CXCR1; SRC; AKT1; MAPK1; PIK3R1; NFKB1; PTK2 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.322E-06 | 1.917E-05 | SLCO1B1; CA2; SLCO1B3; NR1H4; CYP3A4; ABCG2 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 7.832E-06 | 5.051E-05 | GSK3B; AKT1; MAPK1; PIK3R1; PPARA; TP53; NFKB1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.480E-07 | 5.709E-06 | CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 9.067E-06 | 5.372E-05 | GSK3B; CSNK2A1; AKT1; PIK3R1; TP53; NFKB1; TLR2 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.096E-05 | 5.951E-05 | PARP1; LMNA; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.399E-05 | 7.185E-05 | GSK3B; CSNK2A1; CDK1; AKT1; CD38; PIK3R1; TP53; NFKB1 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.046E-05 | 5.846E-05 | PTPN1; GSK3B; AKT1; MAPK1; PIK3R1; PYGL; PTPRF |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 5.410E-06 | 3.671E-05 | HSD11B1; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.802E-05 | 8.561E-05 | MMP2; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 1.517E-05 | 7.583E-05 | CDK1; AKT1; MAPK1; PIK3R1; CDC25B; IGF1R |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.608E-05 | 7.831E-05 | SRC; MMP2; AKT1; MAPK1; PIK3R1; MMP9 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 3.235E-05 | 1.336E-04 | PLA2G1B; KDR; AKT1; MAPK1; PIK3R1; MET; NFKB1; IGF1R |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 8.883E-06 | 5.372E-05 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.366E-05 | 1.361E-04 | ABCC1; PIM1; CYP1B1; MAPK1; TP53; MMP9; MET; NFKB1; CDC25B |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 2.929E-05 | 1.237E-04 | MMP3; AKT1; MAPK1; PIK3R1; MMP9; NFKB1 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.283E-05 | 6.773E-05 | ALK; AKT1; MAPK1; PIK3R1; TP53 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 4.352E-05 | 1.722E-04 | ALOX5; AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.248E-04 | 4.233E-04 | POLB; SRC; CDK1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.037E-04 | 3.583E-04 | CAMK2B; AKT1; MAPK1; PIK3R1; PPARA; NFKB1; TSHR |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 1.492E-04 | 4.972E-04 | SRC; KDR; AKT1; MAPK1; PIK3R1; MET; IGF1R |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 4.782E-05 | 1.747E-04 | ABCC1; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.877E-05 | 1.237E-04 | AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 2.877E-05 | 1.237E-04 | AKT1; MAPK1; PIK3R1; MET; HIF1A |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 2.119E-05 | 9.586E-05 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 4.692E-05 | 1.747E-04 | AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 4.692E-05 | 1.747E-04 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.119E-05 | 9.586E-05 | CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.568E-04 | 5.135E-04 | AKT1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.029E-04 | 3.583E-04 | AKT1; PIK3R1; TP53; NFKB1; PTK2 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 2.517E-04 | 7.839E-04 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 2.750E-04 | 8.427E-04 | AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 3.404E-04 | 9.951E-04 | CAMK2B; ACHE; AKT1; MAPK1; PIK3R1 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 4.127E-04 | 1.181E-03 | CAMK2B; SRC; AKT1; MAPK1; NFKB1; TLR2 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 2.517E-04 | 7.839E-04 | AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.692E-05 | 1.747E-04 | HSD11B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.043E-03 | 2.642E-03 | CAMK2B; GSK3B; CSNK2A1; TP53; PPARD |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.371E-03 | 3.427E-03 | GSK3B; AKT1; PIK3R1; PPARA; NFKB1 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 6.771E-04 | 1.787E-03 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 1.043E-03 | 2.642E-03 | GSK3B; AKT1; MAPK1; PIK3R1; IGF1R |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.674E-03 | 4.026E-03 | CAMK2B; SRC; CD38; MAPK1; PIK3R1 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.674E-03 | 4.026E-03 | PIM1; AKT1; STAT6; PIK3R1; PTPN2 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 2.133E-03 | 4.911E-03 | AKT1; MAPK1; PIK3R1; ADRA2C; ADRA2A |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 2.780E-03 | 6.071E-03 | POLB; GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 2.189E-03 | 4.911E-03 | BACE1; APP; GSK3B; MAPK1; HSD17B10 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 2.613E-03 | 5.773E-03 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 3.317E-03 | 7.162E-03 | CSNK2A1; CDK1; TP53; NFKB1; TLR2 |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.968E-03 | 4.673E-03 | CAMK2B; SRC; ALOX12; PIK3R1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.498E-03 | 3.698E-03 | CAMK2B; SRC; MMP2; MAPK1 |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 2.119E-03 | 4.911E-03 | PIK3R1; NFKB1; PTK2; TLR2 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 4.336E-03 | 9.153E-03 | SRC; AKT1; MAPK1; PIK3R1 |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 2.197E-03 | 4.911E-03 | CAMK2B; AKT1; PYGL; PPARA |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 2.197E-03 | 4.911E-03 | AKT1; MAPK1; PIK3R1; HIF1A |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 4.463E-03 | 9.318E-03 | CAMK2B; CDK1; MAPK1; IGF1R |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.380E-04 | 7.663E-04 | FABP4; AKT1; PIK3R1; TSHR |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 3.851E-03 | 8.220E-03 | MMP2; PIK3R1; MMP9; PTK2 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 4.593E-03 | 9.485E-03 | GSK3B; CDK1; TP53; CDC25B |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 5.725E-03 | 1.133E-02 | AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.248E-02 | 2.215E-02 | AKT1; MAPK1; TP53; NFKB1; CDC25B |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 1.327E-02 | 2.292E-02 | CXCR1; SRC; KDR; MET; IGF1R |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 4.998E-03 | 1.015E-02 | GSK3B; MAPK1; MET; PTK2 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 5.878E-03 | 1.151E-02 | AKT1; MAPK1; PIK3R1; IGF1R |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 8.517E-03 | 1.571E-02 | CAMK2B; AKT1; MAPK1; PIK3R1 |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 8.438E-04 | 2.196E-03 | SRC; PIK3R1; MET; PTK2 |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 7.750E-03 | 1.444E-02 | CXCR1; AKT1; MAPK1; PIK3R1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 3.107E-04 | 9.225E-04 | AKT1; MAPK1; PIK3R1; HIF1A |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.726E-02 | 2.803E-02 | NMUR2; ADRA2C; ADRA2A; DRD4; TSHR |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 2.884E-02 | 4.350E-02 | SRC; MAPK1; PIK3R1; PTK2 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 5.021E-04 | 1.382E-03 | CXCR1; SRC; MET; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 4.226E-04 | 1.181E-03 | CYP2C8; CYP1A2; CYP1A1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 5.308E-04 | 1.441E-03 | CYP2C8; MAOA; CYP1A2; CYP3A4 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 4.226E-04 | 1.181E-03 | RORC; STAT6; NFKB1; TLR2 |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 2.966E-02 | 4.438E-02 | AKT1; PIK3R1; IGF1R |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 1.696E-02 | 2.778E-02 | CAMK2B; GSK3B; MAPK1 |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.398E-02 | 2.351E-02 | AKT1; MAPK1; PIK3R1 |
| hsa05323 | Rheumatoid arthritis_Homo sapiens_hsa05323 | 1.281E-02 | 2.248E-02 | MMP1; MMP3; TLR2 |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 1.522E-02 | 2.537E-02 | CA2; PLA2G1B; CD38 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.206E-02 | 2.161E-02 | SRC; CDK1; MAPK1 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 1.398E-02 | 2.351E-02 | CSNK2A1; PARP1; NFKB1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.133E-02 | 2.050E-02 | MAPK1; PKN1; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 7.242E-03 | 1.362E-02 | MAPK1; NFKB1; TLR2 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 5.950E-03 | 1.154E-02 | AKT1; MAPK1; PIK3R1 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 6.448E-03 | 1.238E-02 | AKT1; PPARA; NFKB1 |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 5.024E-03 | 1.015E-02 | AKT1; PIK3R1; IGF1R |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 5.246E-03 | 1.049E-02 | SRC; MAPK1; NFKB1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 6.327E-05 | 2.268E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa05144 | Malaria_Homo sapiens_hsa05144 | 2.881E-02 | 4.350E-02 | MET; TLR2 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 2.881E-02 | 4.350E-02 | MAOA; NFKB1 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 2.773E-02 | 4.284E-02 | MAPK1; PIK3R1 |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 2.460E-02 | 3.862E-02 | AKT1; PIK3R1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.563E-02 | 3.991E-02 | CYP3A4; XDH |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 2.358E-02 | 3.734E-02 | ABCC1; ABCG2 |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 1.880E-02 | 3.027E-02 | MAPK1; PIK3R1 |
| hsa04975 | Fat digestion and absorption_Homo sapiens_hsa04975 | 2.066E-02 | 3.298E-02 | FABP2; PLA2G1B |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 5.591E-04 | 1.496E-03 | AKR1B10; GAA; AKR1B1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.067E-02 | 1.949E-02 | MAPK1; TP53 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 1.289E-02 | 2.248E-02 | AKR1B10; AKR1B1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.368E-02 | 2.341E-02 | POLB; PARP1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.615E-02 | 2.668E-02 | AKR1B10; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 6.788E-03 | 1.290E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.859E-04 | 8.621E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| C00-D49: Neoplasms | Multiple myeloma | C90 | SRC; IGF1R; CD38 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Dyslipidemia | NA | PPARD |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; AXL; IGF1R; IGF1R; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| NA: NA | Edema | NA | CA2 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; CAMK2B; ACHE; CYP3A4 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; PTPN1; ADRA2C; PPARD; PPARD |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; MMP1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ADRA2C |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; NPSR1; APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; ACHE; ACHE; ACHE; GSK3B; ADRA2C; APP |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ADRA2C |
| C00-D49: Neoplasms | AML | NA | FLT3; KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3; PARP1 |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; SRC |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; ADRA2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; HSD11B1; HSD11B1; PTPN1; GSK3B |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; CA1 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; MMP12; MMP12 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13; MMP12 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | MMP13; ACHE; IGF1R; CDK1; ADRA2C; ADRA2A |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; FLT3; MMP2; TLR2; KDR |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; PARP1; KDR; KDR; KDR; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; PTPN1; PTPN1; NFKB1; GPBAR1; PPARD |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | PARP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; TLR2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC |
| I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; AKT1; HIF1A |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA9; AKT1; MET; CSNK2A1; FLT3; FLT3; MMP2; ACHE; SRC; IGF1R; PTK2; GSK3B; HIF1A; CDK1; MAPK1; MMP9; NFKB1; PIM1; PARP1; CDC25B; CD38; TLR2; TP53; CA1; KDR; APP |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; ADRA2C; CA4; CA4 |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; CYP19A1; FLT3; FLT3; IGF1R; CDK1; KDR; KDR; KDR |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; AKT1; MET; FLT3; MMP2; SRC; IGF1R; PTK2; AURKB; HIF1A; MAPK1; MMP9; TLR2; TP53; KDR; KDR; KDR |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| C00-D49: Neoplasms | Melanoma | C43 | PARP1; TLR2; KDR; KDR |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH |
| C00-D49: Neoplasms | Glioma | C71 | KDR; APP |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| NA: NA | GIST | NA | FLT3 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD4 |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; AURKB; TP53; TP53 |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TP53; KDR; KDR |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; ADRA2C |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; PLA2G1B; ALOX5; MMP3; CAMK2B; MMP1 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ALOX5; ALOX5; MMP12; ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5; MMP1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; ALOX5; MMP12; PPARD |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; AURKB; CD38; TP53 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; ACHE; ADRA2C; CA1; CA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; MMP9; TP53; KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |